Benefits of intralesional injections of sodium thiosulfate in the treatment of calciphylaxis.
Calciphylaxis (CPX) is a rare calcifying thrombotic vasculopathy responsible for painful necrotic ulcers, with a high mortality rate, and its management is often difficult. Recently, intravenous infusions of sodium thiosulfate (STS) have shown efficacy. The aim of this study was to assess the efficacy of intralesional STS (IL STS) in four patients. Our aim was to assess the efficacy of IL STS in a prospective mono-centric open study that included four patients with a biopsy-proven cutaneous CPX. Four women (55-84 years old, mean age: 71·2 years) with a uremic (n = 1) or non-uremic CPX (n = 3) and primary hyperparathyroidism induced by teriparatide or after the initiation of oral anti-vitamin K were treated by IL STS (250 mg/ml). The injections were performed around the ulcers, on the active borders, once or twice a week and then at 1-2 weeks intervals. The injected quantity varied from 1·5 to 15 ml. Pain usually improved after two series of injections. Clinical response was visible after 2 weeks. Three patients (75%) healed completely or almost completely. A failure was observed in the last patient who also had lower limb arteriopathy. The main side effect was the pain during injections. IL STS is an interesting alternative therapeutic option in the management of CPX necrotic ulcers with limited side effects. Larger studies are warranted to precisely define its place, its administration procedure and the patients who could benefit from it.
Department of Dermatology, University of Helsinki and Helsinki University Central Hospital, Helsinki, Finland.
Kirsi
K
Isoherranen
Department of Dermatology, University of Helsinki and Helsinki University Central Hospital, Helsinki, Finland.
Laura
L
Bouchard
Department of Dermatology, University of Helsinki and Helsinki University Central Hospital, Helsinki, Finland.
Nicolas
N
Kluger
D000368:Aged; D000369:Aged, 80 and over; D000931:Antidotes / Q000627:therapeutic use*; D002115:Calciphylaxis / Q000188:drug therapy*; D005260:Female; D006801:Humans; D015552:Injections, Intralesional; D007871:Leg Ulcer / Q000188:drug therapy*; D008875:Middle Aged; D011446:Prospective Studies; D013885:Thiosulfates / Q000627:therapeutic use*
D000931:Antidotes; D013885:Thiosulfates; C017717:sodium thiosulfate
Calcific arteriolopathy; Calciphylaxis; Leg ulcer; Sodium thiosulfate